アジェンダ


Bio-IT World's Second Annual

Bio-IT World Venture, Innovation & Partnering IN-PERSON ONLY
バイオITワールド ベンチャー・イノベーション・提携(対面のみ)

Uniting Investors and Leaders: Advancing Innovation

2025年4月3日 米国東部標準時(EDT)

Join 200+ C-Suite industry stakeholders at the Bio-IT World Venture, Innovation & Partnering Conference on April 3, 2025, in Boston, the US’s top biotech hub. This exclusive single-day event, featuring a highly select group, is part of the renowned Bio-IT World Conference & Expo. This meeting brings together venture capitalists, private equity professionals, bank investors, government partners, start-ups, and industry leaders focusing on investment trends, challenges, and opportunities in biomedical research, drug discovery, and healthcare technology. Additionally, your registration includes access to the Bio-IT World exhibit hall with 150+ emerging businesses, 11 scientific tracks, and networking receptions.

4月3日木曜日

8:00 am

Registration and Networking Coffee

8:30 am

Organizer's Welcome Remarks

8:35 am

Co-Chairperson's Welcome Remarks: Investing in Innovation: The Future of Biotech and Drug Discovery

William T. Mayo, Senior Vice President, Research, IT, Bristol Myers Squibb

8:40 am
PANEL DISCUSSION:

Optimizing Investment Strategies in Biotech

PANEL MODERATOR:

Stephanie Oestreich, Managing Director, Myeloma Investment Fund of the MMRF

Explore the current landscape of biotech investment and partnerships, focusing on timing, pipeline risk, and today's fundraising challenges. The panel will cover strategies for partnership timing, pipeline management, and navigating financial realities to accelerate clinical outcomes.

PANELISTS:

Michelle M. Chen, PhD, Chief Business Officer, InSilico Medicine

Brett B. Cook, Partner, F-Prime Capital

Rana Lonnen, Managing Director, Novartis

Kimberly Nearing, Venture Partner, Investment, BVCF Management Ltd.

9:20 am
PANEL DISCUSSION:

Address the Disconnect between Tech VCs and Biotech

PANEL MODERATOR:

Luba Greenwood, Managing Partner, Binney Street Capital, Dana-Farber Cancer Institute

Address the disconnect between tech VCs and biotech regarding capital intensity, compensation, and board structures. Include pharma’s perspective to identify collaborative strategies for funding successful biotech ventures.

PANELISTS:

Jessica J. Federer, Board Member, Angelini Ventures

Cris De Luca, Partner, Sanofi Ventures

Shana Lawlor, Venture Capital Investor, Founding Managing Partner, 2raze; TotiPotent Capital

Kush M Parmar, Managing Partner, 5AM Ventures

10:00 am
KEYNOTE PRESENTATION:

Investing in the Future of Drug Discovery: Insights for Impactful Investors

Milind Kamkolkar, Venture Partner, RA Capital

Milind Kamkolkar offers a strategic perspective of investment opportunities in drug discovery, focusing on the evolution since the Human Genome Project, the integration of multimodal data, and the infrastructure demands of computational biology. Tailored for investors driving innovation in this sector, his insights bridge cutting-edge science, AI, and data to highlight the transformative potential in precision medicine.

10:15 am

Sponsored Presentation (Opportunity Available)

10:35 am

Networking Coffee Break

11:00 am

Session Moderator's Remarks: Biotech & Tech: Navigating Innovation, Relationships, and Market Trends

Rahul Chaturvedi, Founder & CEO, Clora, Inc.

11:05 am
PANEL DISCUSSION:

The VC & CEO Relationship, Cultivating Enduring Progress

PANEL MODERATOR:

Scott T. Megaffin, CEO, Adiso Therapeutics

Successful biotech companies often rely on strong partnerships between VCs and the CEO. Our highly experienced panelists will delve into the evolution of this critical relationship, sharing their experiences on building trust, navigating challenges, and aligning strategic visions to drive innovation and growth.

PANELISTS:

Andrew Hedin, Partner, Bessemer Venture Partners

Alex Pastuszak, MD, PhD, Co-Founder & CEO, Paterna Biosciences

Claire E. Smith, Partner, SpringTide Ventures

Joanne L. Viney, PhD, Co-Founder & President & CEO, Seismic Therapeutic

11:45 am
PANEL DISCUSSION:

Catalyzing Drug Discovery Innovation-The Role of Private Equity and Banks

PANEL MODERATOR:

Jeremy P. Goldberg, Operating Partner, Healthcare, Arsenal Capital Partners

Examine how private equity and banks drive technological advances in drug discovery, focusing on investments, scaling, and financing strategies.

PANELISTS:

Brian Matesic, Principal, Norwest Venture Partners

Rebecca Stevenson, Head, Healthcare Investment Banking, Americas, HSBC

12:25 pm
FEATURED PRESENTATION:

Executive Perspectives: Steve Pagliuca on Boston’s Pioneering Investments in Technology and Drug Discovery

Steve Pagliuca, Chairman, CEO, and Founder, PagsGroup

12:50 pm

Networking Luncheon

1:45 pm

Session Moderator's Remarks: The Great Debate-Is AI Accelerating the Future of Drug Discovery?

Steven Lehmann, Head of Venture & Founder of Portal Stargaze, Venture, Portal Innovations LLC

1:50 pm

FIRESIDE CHAT: Investing beyond the Molecule: The Future of Drug Discovery

Derek Lowe, PhD, Director, Chemical Biology & Therapeutics, Novartis BioMedical Research

Join Derek Lowe, Director of Chemical Biology Therapeutics at Novartis Institutes for BioMedical Research, and John Keilty, venture capitalist at Third Rock Ventures, for an in-depth conversation on the evolving role of biology in drug discovery. This session will explore cutting-edge developments and their potential to shape future biotech innovations, providing insights essential for investors and industry leaders looking to understand the next wave of transformative therapies.

Interviewed By:

John J. Keilty, Venture Partner, Third Rock Ventures

2:15 pm
PANEL DISCUSSION:

Demystifying AI-Real Examples in Drug Development

PANEL MODERATOR:

Bill Fitzgerald, Head, Biotechnology Markets Americas, Google

Explore how AI is transforming drug development with tangible results. This panel will showcase real-world case studies of AI applications that enhance clinical processes, streamline workflows, and deliver measurable value. Gain clarity on the distinction between AI and generative AI and their unique roles in biotech. With practical demonstrations and insights from industry leaders, this session is designed to equip investors and stakeholders with a comprehensive understanding of AI's potential and its proven ROI in supporting drug discovery.

PANELISTS:

Lucy J Colwell, PhD, Research Scientist, Google UK Ltd

Pat Lorton, CTO and COO, Software, Software & Ops, Schrodinger Inc.

Woody Sherman, PhD, CIO, Psivant Therapeutics

Ajay S. Yekkirala, PhD, Co-Founder & Senior Vice President & Head of Discovery, Superluminal Medicines, Inc.

2:55 pm
Coffee Talk: Round Table Discussions with Refreshments (Sponsorship Opportunity Available)
3:20 pm

Session Moderator's Remarks: Driving Innovation: How Companies Are Redefining Drug Discovery through Emerging Trends and Technologies

Mika Newton, CEO, xCures

3:25 pm
PANEL DISCUSSION:

No-Nonsense AI-Cutting through the Noise

PANEL MODERATOR:

Anna Marie Wagner, Independent Board Member & Advisor, Corporate Development

Equip investors with the right tools to evaluate AI in biotech, emphasizing data quality, validation, and differentiation between hype and innovation.

PANELISTS:

Brad Calvin, Co-Founder & CEO, AsedaSciences, Inc.

Peter Clark, Vice President, Computational Drug Design, Novo Nordisk Inc.

Molly Gibson, Origination Partner, Flagship Pioneering

Stef Van Grieken, Co-Founder & CEO, Cradle Bio

3:55 pm

How Ginkgo’s Strategic Pivots Drive Profitability in Biotech: Unlocking the Secret Sauce of Commercialization Success

Barry Canton, PhD, Co-Founder & CTO, Ginkgo BioWorks, Inc.

4:10 pm
PANEL DISCUSSION:

Investing in the Future of Drug Discovery: Breakthrough Technologies to Watch

PANEL MODERATOR:

Joe Collura, Director, Co-Founder & CEO, Stealth Mode Biotech

Discover where to invest now to capitalize on the future of drug discovery. This panel will spotlight groundbreaking technologies like quantum computing and advanced platforms that are reshaping the industry. Hear from experts on which innovations hold the most promise, and gain insights to guide smart investment decisions for impactful returns.

PANELISTS:

Andrea De Souza, Chief Corporate Development Officer, Qubit Pharmaceuticals

Robert C. Green, MD, MPH, Professor and Director of Genomes2People Research, Mass General Brigham, Broad Institute, Ariadne Labs, and Harvard Medical School

Douglas Selinger, PhD, CEO & Founder, Plex Research Inc.

Mariola Szenk, Investor, BlueYard Capital

4:55 pm

Best of Show Awards Reception in the Exhibit Hall with Poster Viewing

Unwind with colleagues at our lively reception! Explore posters, vote for the best, network with exhibitors, enjoy a drink, and try to win a raffle prize. Celebrate Best of Show winners!

5:45 pm

Close of Summit

* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。